Non-invasive MRI techniques for assessing liver damage in chronic liver disease
Multi-parametric Magnetic Resonance Imaging for the Precise Diagnosis and Quantitative Study of Liver Steatosis, Inflammation, and Fibrosis in Chronic Liver Disease.
This study is testing new MRI techniques to see if they can help doctors better detect liver damage in people with chronic liver disease without needing to do invasive biopsies.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Shengjing Hospital Academic / other |
| Locations | 1 site (Shenyang, Liaoning) |
| Trial ID | NCT06463366 on ClinicalTrials.gov |
What this trial studies
This study aims to develop and validate advanced non-invasive Magnetic Resonance Imaging (MRI) techniques, specifically MR elastography and MRI-PDFF, to accurately assess liver damage in patients with chronic liver disease. By utilizing these innovative imaging methods, the study seeks to improve the detection of liver fibrosis, inflammation, and fat content, thereby reducing the need for invasive liver biopsies. The research will involve regular follow-ups every six months to build a predictive model based on functional MRI metrics. This approach could enhance diagnostic performance and facilitate earlier intervention for patients at risk of severe liver complications.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 to 75 with chronic liver disease, including various forms of hepatitis and cirrhosis.
Not a fit: Patients who are under 18, have contraindications to MRI, or are unable to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could significantly improve the diagnosis and management of chronic liver disease, leading to better patient outcomes and reduced reliance on invasive procedures.
How similar studies have performed: Other studies utilizing non-invasive imaging techniques for liver assessment have shown promise, indicating that this approach is both relevant and potentially effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Chronic liver disease (including viral hepatitis, alcoholic hepatitis, non alcoholic steatohepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, etc..) 2. Age range of 18 to 75 years old 3. Accept systematic antiviral therapy or hormone or ursodesoxycholic acid or supportive liver protection therapy Exclusion Criteria: 1. Age less than 18 years 2. Unable or unwilling to give informed consent 3. Contra-indications to MRI 4. Electrical implants such as cardiac pacemakers or perfusion pumps 5. Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants 6. Ferromagnetic objects such as jewelry or metal clips in clothing 7. Pregnant subjects 8. Pre-existing medical conditions including a likelihood of developing seizures or claustrophobic reactions
Where this trial is running
Shenyang, Liaoning
- Shengjing Hospital of China Medical University — Shenyang, Liaoning, China (Recruiting)
Study contacts
- Study coordinator: Yu Shi
- Email: 18940259980@163.com
- Phone: +86 189 4025 9980
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.